AAPL338.32-6.31 (-1.83%) ▼|ABBV288.84-6.05 (-2.05%) ▼|ABT110.16+3.96 (+3.73%) ▲|ACN260.94+2.70 (+1.05%) ▲|ADBE251.47+1.24 (+0.50%) ▲|AMAT374.53-15.56 (-3.99%) ▼|AMD466.84-37.96 (-7.52%) ▼|AMGN465.45-0.56 (-0.12%) ▼|AMT188.30+0.52 (+0.28%) ▲|AMZN245.63+5.28 (+2.20%) ▲|AVGO322.23-3.85 (-1.18%) ▼|AXP327.98+8.87 (+2.78%) ▲|BA175.40+3.85 (+2.24%) ▲|BAC49.57-0.44 (-0.88%) ▼|BKNG153.75+5.62 (+3.79%) ▲|BLK1,167.15+19.61 (+1.71%) ▲|BMY63.02+0.54 (+0.86%) ▲|BNY147.78+0.67 (+0.46%) ▲|BRK-B556.11+13.62 (+2.51%) ▲|C123.10+1.13 (+0.93%) ▲|CAT613.62-9.13 (-1.47%) ▼|CL97.43+2.14 (+2.25%) ▲|CMCSA23.87+0.65 (+2.80%) ▲|COF210.77+5.92 (+2.89%) ▲|COP146.84-7.19 (-4.67%) ▼|COST1,040.55+28.27 (+2.79%) ▲|CRM226.18-2.99 (-1.30%) ▼|CSCO101.61-2.90 (-2.77%) ▼|CVS88.51-1.74 (-1.93%) ▼|CVX227.77-7.75 (-3.29%) ▼|DE667.60-7.88 (-1.17%) ▼|DHR227.97-4.26 (-1.83%) ▼|DIS113.11+2.17 (+1.96%) ▲|DUK128.38+0.99 (+0.78%) ▲|EMR165.96+1.02 (+0.62%) ▲|FDX318.25+4.97 (+1.59%) ▲|GD373.46+0.87 (+0.23%) ▲|GE315.78+13.98 (+4.63%) ▲|GEV862.25+4.38 (+0.51%) ▲|GILD170.33-0.35 (-0.21%) ▼|GM89.94+2.54 (+2.91%) ▲|GOOG278.04-0.18 (-0.06%) ▼|GOOGL278.99-0.85 (-0.30%) ▼|GS898.72+4.17 (+0.47%) ▲|HD341.15+11.95 (+3.63%) ▲|HON223.77+5.44 (+2.49%) ▲|IBM252.51-5.30 (-2.06%) ▼|INTC59.97-5.79 (-8.80%) ▼|INTU352.10+11.01 (+3.23%) ▲|ISRG436.87+4.86 (+1.13%) ▲|JNJ270.56-2.64 (-0.97%) ▼|JPM340.58+3.54 (+1.05%) ▲|KO95.83+1.75 (+1.86%) ▲|LIN519.72+5.48 (+1.07%) ▲|LLY1,410.99-6.55 (-0.46%) ▼|LMT643.15+6.20 (+0.97%) ▲|LOW218.15+9.08 (+4.34%) ▲|LRCX227.56-11.55 (-4.83%) ▼|MA658.10+20.09 (+3.15%) ▲|MCD265.64+7.52 (+2.91%) ▲|MDLZ66.38+1.44 (+2.22%) ▲|MDT99.29+2.75 (+2.85%) ▲|META606.73-8.26 (-1.34%) ▼|MMM178.36+4.02 (+2.31%) ▲|MO77.17-0.86 (-1.10%) ▼|MRK148.36-1.16 (-0.78%) ▼|MS185.73+1.43 (+0.78%) ▲|MSFT507.12-14.79 (-2.83%) ▼|MU833.59-51.15 (-5.78%) ▼|NEE85.03+1.32 (+1.58%) ▲|NFLX62.34+0.26 (+0.42%) ▲|NKE39.12+0.45 (+1.16%) ▲|NOW106.01+0.89 (+0.85%) ▲|NVDA202.06-2.58 (-1.26%) ▼|ORCL119.22-11.45 (-8.76%) ▼|PEP140.42+3.08 (+2.24%) ▲|PFE30.67+0.15 (+0.49%) ▲|PG163.56+1.99 (+1.23%) ▲|PLTR178.34-5.77 (-3.13%) ▼|PM208.29-0.50 (-0.24%) ▼|QCOM162.08-2.71 (-1.64%) ▼|RTX202.79+2.99 (+1.50%) ▲|SBUX104.40+0.75 (+0.72%) ▲|SCHW88.71+0.66 (+0.75%) ▲|SO94.61+0.90 (+0.96%) ▲|SPG221.73+3.98 (+1.83%) ▲|T21.44+0.03 (+0.14%) ▲|TMO682.65-14.35 (-2.06%) ▼|TMUS160.15+3.71 (+2.37%) ▲|TSLA403.82+4.01 (+1.00%) ▲|TXN302.02+1.18 (+0.39%) ▲|UBER66.71+1.46 (+2.24%) ▲|UNH400.44-6.53 (-1.60%) ▼|UNP307.00+3.00 (+0.99%) ▲|UPS109.71+1.46 (+1.35%) ▲|USB60.49+1.04 (+1.75%) ▲|V425.51+11.92 (+2.88%) ▲|VZ45.05+0.32 (+0.72%) ▲|WFC85.89+2.49 (+2.99%) ▲|WMT127.69+4.18 (+3.38%) ▲|XOM179.67-7.58 (-4.05%) ▼|AAPL338.32-6.31 (-1.83%) ▼|ABBV288.84-6.05 (-2.05%) ▼|ABT110.16+3.96 (+3.73%) ▲|ACN260.94+2.70 (+1.05%) ▲|ADBE251.47+1.24 (+0.50%) ▲|AMAT374.53-15.56 (-3.99%) ▼|AMD466.84-37.96 (-7.52%) ▼|AMGN465.45-0.56 (-0.12%) ▼|AMT188.30+0.52 (+0.28%) ▲|AMZN245.63+5.28 (+2.20%) ▲|AVGO322.23-3.85 (-1.18%) ▼|AXP327.98+8.87 (+2.78%) ▲|BA175.40+3.85 (+2.24%) ▲|BAC49.57-0.44 (-0.88%) ▼|BKNG153.75+5.62 (+3.79%) ▲|BLK1,167.15+19.61 (+1.71%) ▲|BMY63.02+0.54 (+0.86%) ▲|BNY147.78+0.67 (+0.46%) ▲|BRK-B556.11+13.62 (+2.51%) ▲|C123.10+1.13 (+0.93%) ▲|CAT613.62-9.13 (-1.47%) ▼|CL97.43+2.14 (+2.25%) ▲|CMCSA23.87+0.65 (+2.80%) ▲|COF210.77+5.92 (+2.89%) ▲|COP146.84-7.19 (-4.67%) ▼|COST1,040.55+28.27 (+2.79%) ▲|CRM226.18-2.99 (-1.30%) ▼|CSCO101.61-2.90 (-2.77%) ▼|CVS88.51-1.74 (-1.93%) ▼|CVX227.77-7.75 (-3.29%) ▼|DE667.60-7.88 (-1.17%) ▼|DHR227.97-4.26 (-1.83%) ▼|DIS113.11+2.17 (+1.96%) ▲|DUK128.38+0.99 (+0.78%) ▲|EMR165.96+1.02 (+0.62%) ▲|FDX318.25+4.97 (+1.59%) ▲|GD373.46+0.87 (+0.23%) ▲|GE315.78+13.98 (+4.63%) ▲|GEV862.25+4.38 (+0.51%) ▲|GILD170.33-0.35 (-0.21%) ▼|GM89.94+2.54 (+2.91%) ▲|GOOG278.04-0.18 (-0.06%) ▼|GOOGL278.99-0.85 (-0.30%) ▼|GS898.72+4.17 (+0.47%) ▲|HD341.15+11.95 (+3.63%) ▲|HON223.77+5.44 (+2.49%) ▲|IBM252.51-5.30 (-2.06%) ▼|INTC59.97-5.79 (-8.80%) ▼|INTU352.10+11.01 (+3.23%) ▲|ISRG436.87+4.86 (+1.13%) ▲|JNJ270.56-2.64 (-0.97%) ▼|JPM340.58+3.54 (+1.05%) ▲|KO95.83+1.75 (+1.86%) ▲|LIN519.72+5.48 (+1.07%) ▲|LLY1,410.99-6.55 (-0.46%) ▼|LMT643.15+6.20 (+0.97%) ▲|LOW218.15+9.08 (+4.34%) ▲|LRCX227.56-11.55 (-4.83%) ▼|MA658.10+20.09 (+3.15%) ▲|MCD265.64+7.52 (+2.91%) ▲|MDLZ66.38+1.44 (+2.22%) ▲|MDT99.29+2.75 (+2.85%) ▲|META606.73-8.26 (-1.34%) ▼|MMM178.36+4.02 (+2.31%) ▲|MO77.17-0.86 (-1.10%) ▼|MRK148.36-1.16 (-0.78%) ▼|MS185.73+1.43 (+0.78%) ▲|MSFT507.12-14.79 (-2.83%) ▼|MU833.59-51.15 (-5.78%) ▼|NEE85.03+1.32 (+1.58%) ▲|NFLX62.34+0.26 (+0.42%) ▲|NKE39.12+0.45 (+1.16%) ▲|NOW106.01+0.89 (+0.85%) ▲|NVDA202.06-2.58 (-1.26%) ▼|ORCL119.22-11.45 (-8.76%) ▼|PEP140.42+3.08 (+2.24%) ▲|PFE30.67+0.15 (+0.49%) ▲|PG163.56+1.99 (+1.23%) ▲|PLTR178.34-5.77 (-3.13%) ▼|PM208.29-0.50 (-0.24%) ▼|QCOM162.08-2.71 (-1.64%) ▼|RTX202.79+2.99 (+1.50%) ▲|SBUX104.40+0.75 (+0.72%) ▲|SCHW88.71+0.66 (+0.75%) ▲|SO94.61+0.90 (+0.96%) ▲|SPG221.73+3.98 (+1.83%) ▲|T21.44+0.03 (+0.14%) ▲|TMO682.65-14.35 (-2.06%) ▼|TMUS160.15+3.71 (+2.37%) ▲|TSLA403.82+4.01 (+1.00%) ▲|TXN302.02+1.18 (+0.39%) ▲|UBER66.71+1.46 (+2.24%) ▲|UNH400.44-6.53 (-1.60%) ▼|UNP307.00+3.00 (+0.99%) ▲|UPS109.71+1.46 (+1.35%) ▲|USB60.49+1.04 (+1.75%) ▲|V425.51+11.92 (+2.88%) ▲|VZ45.05+0.32 (+0.72%) ▲|WFC85.89+2.49 (+2.99%) ▲|WMT127.69+4.18 (+3.38%) ▲|XOM179.67-7.58 (-4.05%) ▼|
11.6 C
New York
Tuesday, November 3, 2026

Tag: officer

newsFORsourcecompanycontentinformationreleases1market

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.

Arrivia and KrisFlyer Expand Partnership to Launch Cruise Redemptions with Miles

SINGAPORE, June 8, 2026 /PRNewswire/ -- arrivia and KrisFlyer, the lifestyle rewards programme of the Singapore Airlines Group, are elevating member benefits with the...

Casino Group Communication

Casino Group and the Zouari Family strengthen their historic partnership to accelerate in convenience retail

New IBM Study Finds CIOs and CTOs Face Growing AI Control Gap as Enterprise Deployment Scales

Most surveyed technology leaders are accountable for systems they don't fully controlOnly 11% of respondents say they're completely prepared for the scale of AI...

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for...

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas 
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

Canadian Employers Invited to Create 10,000 New Opportunities Through National Inclusive Hiring Campaign

Enabled Talent launches One Company. One Talent, inviting Canadian employers to create one inclusive opportunity and build a stronger workforce.

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

Dietz & Watson Expands Its Premium Deli Chicken Lineup with Launch of Heritage Roast and Cantina Chicken Breast at IDDBA 2026

New sliced-to-order flavors deliver comforting tradition and vibrant, globally inspired taste 
New sliced-to-order flavors deliver comforting tradition and vibrant, globally inspired taste

IBA‑UIBC Cup of Bakers 2027 “Golden Statue Cup” China Selection – Hong Kong & Macao SAR Selection Competition Successfully Held in Hong Kong

Competition Highlights Industry Excellence and Strengthens International Exchange in the Baking Sector HONG KONG, June 7, 2026 /PRNewswire/ -- The Final of the IBA‑UIBC Cup...

Unlocking the Americas: Air Canada and Abra Group Sign Memorandum to Expand Travel and Connectivity between Canada, Latin America and Beyond

RIO DE JANEIRO, June 07, 2026 (GLOBE NEWSWIRE) -- Air Canada and Abra Group today announced they have signed a Memorandum of Understanding to develop a broad, long-term strategic partnership. The agreement between Canada’s largest airline and the Latin American air transport company, whose carriers include the Avianca and GOL brands, would enable the partners to expand their global reach, providing customers and shippers greater connectivity across North, Central and South America and beyond. Any final agreement is subject to final documentation and regulatory approval.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOfficer

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers